✦ LIBER ✦

Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s lymphoma patients

✍ Scribed by Rigacci, Luigi; Puccini, Benedetta; Cortelazzo, Sergio; Gaidano, Gianluca; Piccin, Andrea; D’Arco, Alfonso; Freilone, Roberto; Storti, Sergio; Orciuolo, Enrico; Zinzani, Pier Luigi; Zaja, Francesco; Bongarzoni, Velia; Balzarotti, Monica; Rota-Scalabrini, Delia; Patti, Caterina; Gobbi, Marco; Carpaneto, Andrea; Liberati, Anna Marina; Bosi, Alberto; Iannitto, Emilio

Book ID: 111692160
Publisher: Springer
Year: 2012
Tongue: English
Weight: 317 KB
Volume: 91
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-012-1422-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Severe myelotoxicity of oral etoposide i

Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia

✍ Sharon Shaklai; Osnat Bairey; Dorit Blickstein; Miron Prokocimer; Herzlia Hadar; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 406 KB 👁 2 views

## BACKGROUND. Promising results have been reported for patients with non-Hodgkin's lymphoma (NHL) receiving chronic oral etoposide. Due to the small number of patients reported, information regarding side effects is limited, and therefore warrants further evaluation. ## METHODS. Twenty eligible

Introduction: Treatment of Patients With

Introduction: Treatment of Patients With Rituximab-Refractory Indolent Non-Hodgkin’s Lymphoma

✍ Stephanie A. Gregory 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Bendamustine for the treatment of chroni

Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma

✍ Trevor W. Dennie; Jill M. Kolesar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 209 KB

First-line and maintenance treatment wit

First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma

✍ John D Hainsworth 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 120 KB

Fludarabine, cyclophosphamide, and ritux

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-hodgkin lymphoma

✍ Constantine S. Tam; Max Wolf; H. Miles Prince; E. Henry Januszewicz; David Weste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB 👁 1 views

A randomized phase 2 study of PBPC mobil

A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin’s disease or non-Hodgkin’s lymphoma

✍ Stiff, P; Gingrich, R; Luger, S; Wyres, M R; Brown, R A; LeMaistre, C F; Perry, 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 122 KB